Diabetes epidemiology: Guiding clinical and public health practice: The Kelly West Award Lecture, 2006

Diabetes Care

Volumn 30, Issue 7, 2007, Pages 1912-1919

  Herman, William H ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC RETINOPATHY; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; PRACTICE GUIDELINE; PREVALENCE; PUBLIC HEALTH SERVICE; SCREENING TEST;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; HUMANS; MASS SCREENING; MIDDLE AGED; MODELS, BIOLOGICAL; PUBLIC HEALTH PRACTICE;

EID: 34447134712     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-9924     Document Type: Conference Paper

References (53)

1. Fajans SS, Conn JW: Prediabetes, subclinical diabetes, and latent clinical diabetes: Interpretation, diagnosis and treatment. In On the Nature and Treatment of Diabetes. Leibel BS, Wrenshall GA, Eds. New York, 1965, p. 641-656
2. Bennett PH, Rushforth NB, Miller M, Lecompte PM: Epidemiologic studies of diabetes in Pima Indians. Recent Prog Horm Res 32:333-376, 1976
3. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979
4. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
5. Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ, Badran A, Sous ES, Ali MA: Comparison of fasting and 2-hour glucose and HbA1C levels for diagnosing diabetes. Diabetes Care 20:785-791, 1997
6. Hamman RF: Retinopathy in recent-onset diabetes and persons at high risk of diabetes in the Diabetes Prevention Program. Late-breaking abstract presented at the 65th Annual Meeting of the American Diabetes Association, 10-14 June 2005, at the San Diego Convention Center, San Diego, California
7. Metcalf PA, Baker JR, Scragg RKR, Dryson E, Scott AJ, Wild CJ: Microalbuminuria in a middle-aged workforce. Diabetes Care 16:1485-1493, 1993
8. Herman WH, Aubert RE, Engelgau MM, Thompson TJ, Ali MA, Sous ES, Hegazy M, Badran A, Kenny SJ, Gunter EW, Malarcher AM, Brechner RJ, Wetterhall SF, DeStefano F, Smith PJ, Habib M, abd el Shakour S, Ibrahim AS, Behairy EME: Diabetes mellitus in Egypt: glycaemic control and microvascular and neuropathic complications. Diabet Med 15:1045-1051, 1998
9. Singleton JR, Smith AG, Bromberg MB: Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 24:1448-1453, 2001
10. The DECODE Study Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 26:688-696, 2003
11. Remein QR, Wilkerson HLC: The efficiency of screening tests for diabetes. J Chronic Dis 13:6-21, 1961
12. Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB, Goldstein DE, for the NGSP Steering Committee: The national glycohemoglobin standardization program: a five-year progress report. Clin Chem 47:1985-1992, 2001
13. Meigs JB, Nathan DM, Cupples LA, Wilson PW, Singer DE: Tracking of glycated hemoglobin in the original cohort of the Framingham-Heart Study. J Clin Epidemiol 49:411-417, 1996
14. Yudkin JS, Forrest RD, Jackson CA, Ryle AJ, Davie S, Gould BJ: Unexplained variability of glycated hemoglobin in non-diabetic subjects not related to glycaemia. Diabetologia 33:208-215, 1990
15. 1C levels for children and young adults in the U.S.: Third National Health and Nutrition Examination Survey. Diabetes Care 25:1326-1330, 2002
16. Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, Heise MA, Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH, for ADOPT Study Group: A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of type 2 diabetic patients in North America and Europe. Diabet Med 23:1289-1294, 2006
17. Engelgau MM, Venkat Narayan KM, Herman WH: Screening for type 2 diabetes. Diabetes Care 23:1563-1580, 2000
18. CDC Diabetes Cost-Effectiveness Study Group: Screening for type 2 diabetes: Is it cost-effective? JAMA 280:1757-1763, 1998
19. Johnson SL, Tabaei BP, Herman WH: The efficacy and cost of alternative strategies for systematic screening for type 2 diabetes in the U.S. population 45-74 years of age. Diabetes Care 28:307-311, 2005
20. Tabaei BP, Herman WH: A multivariate logistic regression equation to screen for diabetes: development and validation. Diabetes Care 25:1999-2003, 2002
21. Baan CA, Ruige JB, Stolk RP, Witteman JCM, Dekker JM, Heine RJ, Feskens EJM: Performance of a predictive model to identify undiagnosed diabetes in a health care setting. Diabetes Care 22:213-219, 1999
22. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ: Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabete Metab Res Rev 16:164-171, 2000
23. Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K: A Danish diabetes risk score for targeted screening: the Inter99 Study. Diabetes Care 27:727-733, 2004
24. Ramachandran A, Snehalatha C, Vijay V, Wareham NJ, Colaguiri S: Derivation and validation of diabetes risk score for urban Asian Indians. Diabetes Res and Clinical Practice 70:63-70, 2005
25. Herman WH, Sinnock P, Brenner E, Brimberry JL, Langford D, Nakashima A, Sepe SJ, Teutsch SM, Mazze RS: An epidemiologic model for diabetes mellitus: incidence, prevalence, and mortality. Diabetes Care 4:367-371, 1984
26. Centers for Disease Control and Prevention: National Diabetes Surveillance System: Prevalence of Diabetes: Number (in Millions) of Persons With Diagnosed Diabetes, United States, 1980-2005 [article online]. Available from http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm. Accessed 18 May 2006
27. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431, 1998
28. Herman WH, Ali MA, Aubert RE, Engelgau MM, Kenny SJ, Gunter EW, Malarcher AM, Brechner RJ, Wetterhall SF, DeStefano F, Thompson TJ, Smith PJ, Badran A, Sous ES, Habib M, Hegazy M, abd el Shakour S, Ibrahim AS, el Moneim el Behairy A: Diabetes mellitus in Egypt: risk factors and prevalence. Diabet Med 12:1126-1131, 1995
29. Jaber LA, Brown MB, Hammad A, Nowak SN, Zhu Q, Ghafoor A, Herman WH: Epidemiology of diabetes among Arab Americans. Diabetes Care 26:308-313, 2003
30. Herman WH, Teutsch SM, Geiss LS: The Carter Center of Emory University: closing the gap: the problem of diabetes mellitus in the United States. Diabetes Care 8:391-406, 1985
31. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
32. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, for the Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
33. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
34. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, Indian Diabetes Prevention Programme (IDPP): The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:289-297, 2006
35. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
36. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381-389, 2000
37. The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563-2569, 2002
38. The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. JAMA 290:2159-2167, 2003
39. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653, 2005
40. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE: The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 142:323-332, 2005
41. Herman WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, Lachin JM, Engelgau MM: The Diabetes Prevention Program Research Group: costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care 26:36-47, 2003
42. Herman WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, Lachin JM, Engelgau MM, the Diabetes Prevention Program Research Group: Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 26:2518-2523, 2003
43. Brandle M, Zhou H, Smith BRK, Marriott D, Burke R, Tabaei BP, Brown MB, Herman WH: The direct medical cost of type 2 diabetes mellitus. Diabetes Care 26:2300-2304, 2003
44. Coffey JT, Brandle M, Zhou H, Marriott D, Burke R, Tabaei BP, Engelgau MM, Kaplan R, Herman WH: Valuing health-related quality of life in diabetes. Diabetes Care 25:2238-2243, 2002
45. Caro JJ, Getsios D, Caro I, Klittich WS, O'Brien JA: Economic evaluation of therapeutic interventions to prevent type 2 diabetes in Canada. Diabet Med 21:1229-1236, 2004
46. Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ: Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: Modeling the long-term health economic implications of the Diabetes Prevention Program in Australia, France, Germany, Switzerland, and the United Kingdom. Clinical Therapeutics 26:304-321, 2004
47. Eddy DM, Schlessinger L, Kahn R: Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 143:251-264, 2005
48. TRIAD Study Group: The Translating Research Into Action for Diabetes (TRIAD) study: a multicenter study of diabetes in managed care. Diabetes Care 25:386-389, 2002
49. Kim C, Williamson DF, Mangione CM, Safford MM, Selby JV, Marrero DG, Curb JD, Thompson TJ, Narayan KM, Herman WH, the TRIAD Study Group: Managed care organization and the quality of diabetes care: the Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care 27:1529-1534, 2004
50. Ettner SL, Thompson TJ, Stevens MR, Mangione CM, Kim C, Neil Steers W, Goewey J, Brown AF, Chung RS, Venkat Narayan KM, the TRIAD Study Group: Are physician reimbursement strategies associated with processes of care and patient satisfaction for patients with diabetes in managed care? Health Serv Res 41:1221-1241, 2006
51. Karter AJ, Stevens MR, Herman WH, Ettner S, Marrero DG, Safford MM, Engelgau MM, Curb JD, Brown AF, the TRIAD Study Group: Out-of-pocket costs and diabetes preventive services: the Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care 26:2294-2299, 2003
52. Kim C, Williamson DF, Herman WH, Safford MM, Selby JV, Marrero DG, Curb JD, Thompson TJ, Narayan KM, Mangione CM, the TRIAD Study Group: Referral management and the care of patients with diabetes: the Translating Research Into Action for Diabetes (TRIAD) study. Am J Manag Care 10:137-143, 2004
53. Mangione CM, Gerzoff RB, Williamson DF, Steers WN, Kerr EA, Brown AF, Waitzfelder BE, Marrero DG, Dudley RA, Kim C, Herman W, Thompson TJ, Safford MM, Selby JV, the TRIAD Study Group: The association between quality of care and the intensity of diabetes disease management programs. Ann Intern Med 145:107-116, 2006